darglitazone has been researched along with 2,4-thiazolidinedione in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, J; Diaz, E; Hayes, N; Smith, R; Szalkowski, D; Zhang, B | 1 |
| Brown, TA; Healy, DR; Ke, HZ; Li, M; Li, Y; Pan, LC; Robinson, BS; Simmons, HA | 1 |
2 other study(ies) available for darglitazone and 2,4-thiazolidinedione
| Article | Year |
|---|---|
Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Muscles; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Pioglitazone; Protein-Tyrosine Kinases; Rats; Receptor, Insulin; Signal Transduction; Thiazoles; Thiazolidinediones | 1994 |
Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
Topics: Adipogenesis; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Bone Marrow Cells; Bone Resorption; Cells, Cultured; Dose-Response Relationship, Drug; Femur; Gene Expression; Male; Mice; Mice, Inbred C57BL; Organ Size; Osteoclasts; Osteogenesis; PPAR gamma; Thiazolidinediones; Time Factors; Tomography, X-Ray Computed | 2006 |